Botulinum toxin for spastic GI disorders: a systematic review.
Zhao
Xiaotuan
X
Enteric Neuromuscular Disorders and Pain (END Pain) Program, Division of Gastroenterology and Hepatology, University of Texas Medical Branch, Galveston 77555, USA.
Pasricha
Pankaj Jay
PJ
D018726:Anti-Dyskinesia Agents / Q000009:adverse effects / Q000627:therapeutic use*; D001905:Botulinum Toxins / Q000009:adverse effects / Q000627:therapeutic use*; D002986:Clinical Trials as Topic; D004305:Dose-Response Relationship, Drug; D004931:Esophageal Achalasia / Q000175:diagnosis / Q000188:drug therapy*; D005260:Female; D005500:Follow-Up Studies; D005767:Gastrointestinal Diseases / Q000175:diagnosis* / Q000188:drug therapy*; D006801:Humans; D015552:Injections, Intralesional; D008297:Male; D009128:Muscle Spasticity; D018579:Patient Selection; D018570:Risk Assessment; D016896:Treatment Outcome
D018726:Anti-Dyskinesia Agents; D001905:Botulinum Toxins